Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Fraxetin
Cat. No.:
OB0125LY-089
Appearance:
Solid
Purity:
99.7%
Identity:
Confirmed by NMR and HPLC.
Size:
Add to basket
Product Overview
Description:
Fraxetin has biological activities such as antioxidant, anti-inflammatory and anti-tumor. It has a marked inhibitory effect on S.aureus proliferation.
Synonym:
574-84-5; 7,8-Dihydroxy-6-methoxy coumarin; 7,8-Dihydroxy-6-methoxy-2H-chromen-2-one; 7,8-Dihydroxy-6-methoxycoumarin; 7,8-Dihydroxy-6-methoxychromen-2-one; 2H-1-Benzopyran-2-one, 7,8-dihydroxy-6-methoxy-; 7,8-Dihydroxy-6-methoxy-chromen-2-one; 7,8-Dihydroxy-6-methoxy-2-benzopyrone; Fraxetin (7,8-dihydroxy-6-methoxycoumarin)
CAS No.:
574-84-5
Compound CID:
5273569
Formula:
C10H8O5
Formula Weight:
208.17
Specification
Relative Density:
1.508 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Fraxetin has major applications in the development of anti-inflammatory, antibacterial and antioxidant agents. It has also been studied for improving metabolic health and cardiovascular health.
Library Information
Targets:
Apoptosis
Receptors:
Apoptosis
Pathways:
Apoptosis
Plate Number:
AOCL-31
Plate Location:
e11
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
13 mg/mL; 62.45 mM
